-
Mashup Score: 1
Lova Sun, MD, discusses genetic alterations in thyroid cancer, including RET and NTRK alterations, and how these can affect treatment options.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2A Look at the Latest Advancements in Thyroid Cancer Treatment - 19 day(s) ago
Lori J. Wirth, MD, discusses imaging techniques, biomarker identification, and promising treatments on the horizon in the thyroid cancer space.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Bilaterality, not multifocality, is an independent risk factor for recurrence in low-risk papillary thyroid cancer - 1 month(s) ago
AbstractBackground. The impact of multifocality and bilaterality on recurrence in patients with low-risk papillary thyroid cancer (PTC) is relevant when conside
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Selpercatinib and its Future in RET-Mutated Thyroid Cancer - 2 month(s) ago
Marcia S. Brose, MD, PhD, FASCO, discusses her hopes for the future of selpercatinib in treating advanced or metastatic RET-mutant thyroid cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Thyroid Cancer Relapse Associated With Age and Metastases - 4 month(s) ago
Results from a retrospective study found that patients with certain features were at a greater risk of recurrence of papillary thyroid cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Worden Reviews Positive Data of Cabozantinib in RAI-Refractory DTC - 5 month(s) ago
In an interview with Targeted Oncology, Francis P. Worden, MD, discussed data from the COSMIC-311 study which support treatment with cabozantinib for patients with radioiodine-refractory differentiated thyroid cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Anlotinib Shows PFS Improvements in Patients With Thyroid Cancer - 6 month(s) ago
Patients had longer median progression-free survival rates with anlotinib vs with placebo in a phase 2 trial, but overall survival data were still immature.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Safety of TKIs in Treatment of Differentiated Thyroid Cancer - 6 month(s) ago
Warren C. Swegal, MD, discusses the safety and tolerability of tyrosine kinase inhibitors for patients with radioactive iodine–refractory differentiated thyroid cancer.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Advances from the LIBRETTO Program in Thyroid Cancer - 7 month(s) ago
Marcia S. Brose, MD, PhD, FASCO, discusses trials LIBRETTO program leading up to LIBRETTO-531.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Investigators have shared final results from the first prospective study of a BRAK/MEK inhibitor combination in patients with advanced rare cancer, including anaplastic thyroid cancer.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
In this video, @LovaSunMD @PennMedicine discusses genetic alterations in thyroid cancer, including RET and NTRK alterations, and how these can affect treatment options. #THYCSM https://t.co/RSBXlyR6ad